EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Brian Bicknell, Ann Liebert, Geoffrey Herkes

Journal of Personalized Medicine · 19.01.2024 · 14 (1) · 112

DOI: 10.3390/jpm14010112 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 19.01.2024. Verfasst von Brian Bicknell und 2 weiteren Autor:innen. Beteiligte Einrichtung: NICM Health Research Institute, University of Western Sydney, Westmead 2145, Australia. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease is the second most common neurodegenerative disease and is increasing in incidence. The combination of motor and non-motor symptoms makes this a devastating disease for people with Parkinson’s disease and their care givers. Parkinson’s disease is characterised by mitochondrial dysfunction and neuronal death in the substantia nigra, a reduction in dopamine, accumulation of α-synuclein aggregates and neuroinflammation. The microbiome–gut–brain axis is also important in Parkinson’s disease, involved in the spread of inflammation and aggregated α-synuclein. The mainstay of Parkinson’s disease treatment is dopamine replacement therapy, which can reduce some of the motor signs. There is a need for additional treatment options to supplement available medications. Photobiomodulation (PBM) is a form of light therapy that has been shown to have multiple clinical benefits due to its enhancement of the mitochondrial electron transport chain and the subsequent increase in mitochondrial membrane potential and ATP production. PBM also modulates cellular signalling and has been shown to reduce inflammation. Clinically, PBM has been used for decades to improve wound healing, treat pain, reduce swelling and heal deep tissues. Pre-clinical experiments have indicated that PBM has the potential to improve the clinical signs of Parkinson’s disease and to provide neuroprotection. This effect is seen whether the PBM is directed to the head of the animal or to other parts of the body (remotely). A small number of clinical trials has given weight to the possibility that using PBM can improve both motor and non-motor clinical signs and symptoms of Parkinson’s disease and may potentially slow its progression.

Schlagwörter

Stichwörter der Autor:innen

Parkinson’s diseaseneuroprotectionphotobiomodulationremotetranscranial

Autor:innen und Institutionen

  • NICM Health Research Institute, University of Western Sydney, Westmead 2145, Australia.
  • Sydney Adventist Hospital, Wahroonga 2076, Australia.
  • Faculty of medicine and Health, Sydney University, Camperdown 2050, Australia.
  • Neurologist, Sydney Adventist Hospital, Wahroonga 2076, Australia.
  • College of Health and Medicine, Australian National University, Canberra 2600, Australia.

Zitieren

APA

Bicknell, B., Liebert, A., & Herkes, G. (2024). Parkinson’s Disease and Photobiomodulation: Potential for Treatment. Journal of Personalized Medicine, 14(1), 112. https://doi.org/10.3390/jpm14010112

Vancouver

Bicknell B, Liebert A, Herkes G. Parkinson’s Disease and Photobiomodulation: Potential for Treatment. Journal of Personalized Medicine. 2024;14(1):112. doi:10.3390/jpm14010112

BibTeX
@article{Bicknell2024,
  author = {Bicknell, Brian and Liebert, Ann and Herkes, Geoffrey},
  title = {Parkinson’s Disease and Photobiomodulation: Potential for Treatment},
  journal = {Journal of Personalized Medicine},
  year = {2024},
  volume = {14},
  number = {1},
  pages = {112},
  doi = {10.3390/jpm14010112}
}
Kostenlos starten →